Showing 20 of 223 recruiting trials for “acute-promyelocytic-leukemia”
Cladribine Venetoclax in Monocytic AML
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
RecruitingNCT06116318 ↗
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia
Universal CAR-T Cells Targeting AML
Universal 4SCAR7U Targeting CD7-positive Malignancies
RecruitingNCT05809284 ↗
Determining the Mechanisms of Loss of CAR T Cell Persistence
👨⚕️ Persis Amrolia, BSc,MBBS,PhD, UCL Institute of Child Health📍 3 sites📅 Started Oct 2023View details ↗
Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy
👨⚕️ Hui Wei, MD, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Oct 2023View details ↗
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
👨⚕️ Nicola Goekbuget, MD, Department of Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany📍 85 sites📅 Started Jul 2023View details ↗
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
RecruitingNCT05902416 ↗
Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →